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Abstract The objective of this study was to review the
efﬁcacy and safety of frovatriptan (F) versus rizatriptan
(R), zolmitriptan (Z) and almotriptan (A), in women with
menstrually related migraine (IHS criteria) through a
pooled analysis of three individual studies. Subjects with a
history of migraine with or without aura were randomized
to F 2.5 mg or R 10 mg (study 1), F or Z 2.5 mg (study 2),
and F or A 12.5 mg (study 3). The studies had an identical
multicenter, randomized, double-blind, crossover design.
After treating three episodes of migraine in no more than
3 months with the ﬁrst treatment, patients had to switch to
the next treatment for other 3 months. 346 subjects formed
intention-to-treat population of the main study; 280 of them
were of a female gender, 256 had regular menses and 187
were included in the menstrual migraine subgroup analysis.
Rate of pain free at 2, 4 and 24 h was 23, 52 and 67 % with
F and 30, 61 and 66 % with comparators (P = NS). Pain
relief episodes at 2, 4 and 24 h were 37, 60 and 66 % for F
and 43, 55 and 61 % for comparators (P = NS). Rate of
recurrence was signiﬁcantly (P\0.05) lower under F
either at 24 h (11 vs. 24 % comparators) or at 48 h (15 vs.
26 % comparators). Number of menstrual migraine attacks
associated with drug-related adverse events was equally
low (P = NS) between F (5 %) and comparators (4 %).
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Introduction
In more than 50 % of women with migraine, the migraine
attack is often associated with the menstrual cycle [1, 2].
These headache attacks are reported to be particularly
severe, more disabling, more difﬁcult to manage, and need
immediate acute or preventive treatment with a drug
capable of ensuring a sustained effect [3].
The efﬁcacy and safety of triptans in the management of
menstrual migraine, either as acute therapy or intermittent
prophylaxis, have been demonstrated in numerous ran-
domized clinical trials [4]. Following this evidence, these
drugs are now recommended as ﬁrst-line treatment for
menstrual migraine [5, 6].
Frovatriptan is an antimigraine agent of the triptan class
developed in order to provide a triptan with the clinical
potential for a long duration of action and a low likelihood
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analyses of three double-blind, randomized, crossover,
head-to-head trials have compared the efﬁcacy and safety
of frovatriptan with that of rizatriptan [8], zolmitriptan [9]
and almotriptan [10] in women with menstrual migraine.
These studies showed a similar efﬁcacy of frovatriptan,
rizatriptan, zolmitriptan and almotriptan in the immediate
treatment of menstrual migraine, but lower recurrence
rates, and thus a better sustained relief under frovatriptan.
In the present paper, we report on results of a pooled
efﬁcacy and safety analysis of frovatriptan versus the
comparators in menstruating women based on the afore-
mentioned publications.
Methods
Study population and design
The original study design of the three studies, including
patient’s selection criteria, is detailed in the original pub-
lications [8–10]. Brieﬂy, the studies recruited subjects of
both genders, aged 18–65 years, with a current history of
migraine with or without aura, according to the Interna-
tional Headache Society deﬁnition [11], and with at least
one, but no more than 6 migraine attacks per month for
6 months prior to entering the study. The analysis of this
subgroup population was predeﬁned in the statistical
analysis plan and original protocols of the three studies.
This condition was deﬁned according to the IHS research
criteria, as migraine without aura attacks in a menstruating
woman, occurring on day 1 ± 2 (namely days -2t o?3)
of menses in at least two out of three menstrual cycles and
additionally at other times of the cycle [11].
The studies had a multicenter, randomized, double-blind,
crossover design and involved 33 different centers across
Italy. Each patient received frovatriptan 2.5 mg or rizatrip-
tan 10 mg in the ﬁrst study [8], frovatriptan 2.5 mg or
zolmitriptan 2.5 mg in the second study [9] and frovatriptan
2.5 mg or almotriptan 12.5 mg in the third study [10]i na
randomized sequence. After treating a maximum of three
episodes of migraine in no more than 3 months with the ﬁrst
treatment,thepatientswitchedtotheothertreatmentandwas
askedtotreatamaximumofthreeepisodesofmigraineinno
more than 3 months with the second treatment.
The study involved three visits and each patient’s par-
ticipation time in the study was not to exceed 6 months
from randomization. Subjects having no migraine episodes
during one of the two observation periods were excluded
from the study.
Randomization was done by blocks of four. Blindness
was ensured by the overencapsulation technique, i.e., by
inserting study drug tablets in capsules.
Data analysis
This pooled analysis was carried out in all menstruating
women randomized to any of the two treatment sequences
foreseen in each study, enrolled to receive either study
treatment and having treated at least one episode of men-
strual migraine with both medications in each study.
The following endpoints were evaluated [11]: (a) the
proportionofpainreliefepisodesat2,4and24 h(adecrease
inmigraineintensityfromsevereormoderatetomildornone
at2,4and24 h);(b)theproportionofpainfreeepisodesat2,
4and24 h(the absence ofmigraine episodesat2,4and24 h
after intake of one dose of study drug); (c) recurrence within
24 h (episodes pain free at 2 h and headache of any severity
returns within 24 h); (d) recurrence within 48 h.
Safety analysis was applied to the intention-to-treat
population, by calculating the incidence of drug-related
adverse events.
Continuous variables were summarized by computing
average values and standard deviations (SD), while cate-
gorical variables by computing the absolute value and the
frequency (as percentage). Study endpoints were compared
between groups by a t test of Student (continuous vari-
ables) or by a Chi-square test (categorical variables).
Kaplan–Meier curves for the cumulative hazard of recur-
rence over the 48 h were also drawn. The level of statistical
signiﬁcance was kept at 0.05 for all analyses.
Results
Baseline demographic and clinical data
The main study population consisted of 346 subjects, of
whom 280 were women and 236 in the fertile age [8–10]. A
total of 187 out of the 236 eligible women treated at least
one episode of menstrual migraine with both medications
and were thus included in the present analysis.
Demographic and clinical baseline data of the 346
patients of the three main studies pooled together and of the
subgroup of 187 women with menstrually related migraine
are reported in Table 1. No statistically signiﬁcant differ-
ences were observed between the whole study population
and the subgroup.
Efﬁcacy results
Atotalof401outoftheoverall1,978attackswereclassiﬁedas
menstruallyrelated:199(20 %)weretreatedwithfrovatriptan
and 202 (20 %) with comparators (66 women treated with
rizatriptan, 54 with zolmitriptan and 67 with almotriptan).
As summarized in Table 2, at 2, 4 and 24 h the rates
of pain relief episodes were not signiﬁcantly (P = NS)
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comparators (43, 55 and 61 %, respectively). Also, the
proportions of pain free episodes at 2, 4 and 24 h did not
differ (P = NS) between treatments (23, 52 and 67 %
frovatriptan vs. 30, 61 and 66 % comparators).
Conversely, the rate of recurrent episodes at 24 h was
signiﬁcantly (P\0.05) lower under frovatriptan (11 vs.
24 % with comparators, Table 2). This was also the case
for recurrence at 48 h (15 % frovatriptan vs. 26 % com-
parators, P\0.05, Table 2). Differences in cumulative
hazard of recurrences over the 48 h were in favor of
frovatriptan (Fig. 1).
Safety results
A total of 18 drug-related adverse events were recorded in
401 treated menstrually related attacks. No statistically
signiﬁcant differences were observed in the rate of attacks
associated with drug-related adverse events between
frovatriptan (10/189 attacks, 5 %) and the comparators
(8/194, 4 %).
Discussion
In this pooled analysis of three double-blind, randomized,
direct comparative, crossover studies [8–10], acute treat-
ment of menstrually related migraine with frovatriptan and
other triptans (rizatriptan, zolmitriptan and almotriptan),
resulted in similar proportions of pain relief and pain free
episodes at 2, 4 and 24 h. Despite a similar immediate
antimigraine efﬁcacy proﬁle of the studied drugs, frova-
triptan showed a more sustained relieving effect on
migraine, with lower headache recurrence rates over 24 h
and even more so over 48 h. Such differences might be
Table 1 Demographic and
clinical baseline data of the 346
patients of the three main
studies pooled together and of
the subgroup of 187 women
with menstrually related
migraine
Data are shown as mean (±SD)
or absolute (n) and relative
frequency (%)
a Numbers refer to number and
frequency of attacks with
respect to overall number of
attacks
Main studies
(n = 346)
Subgroup of
menstruating
women (n = 187)
P
Age (years, mean ± SD) 38 ± 10 36 ± 8N S
Height (cm, mean ± SD) 166 ± 7 164 ± 6N S
Weight (kg, mean ± SD) 64 ± 13 61 ± 9N S
Age at onset of migraine (years, mean ± SD) 17 ± 71 6 ± 6N S
Migraine attack duration[2 days (n, %) 72 (21) 42 (22) NS
No use of triptans in the previous 3 months (n, %) 146 (42) 83 (44) NS
Moderate or severe attacks (n,% )
a 1,574 (80) 327 (82) NS
Patients with at least one moderate
or severe attack (n,% )
334 (97) 179 (96) NS
Table 2 Main study endpoints in the two study treatment groups
(frovatriptan and other triptans)
Frovatriptan Comparators P
Pain relief episodes at 2 h 74 (37) 87 (43) NS
Pain free episodes at 2 h 46 (23) 60 (30) NS
Pain relief episodes at 4 h 120 (60) 113 (55) NS
Pain free episodes at 4 h 104 (52) 124 (61) NS
Pain relief episodes at 24 h 133 (66) 124 (61) NS
Pain free episodes at 24 h 133 (67) 133 (66) NS
Recurrent episodes at 24 h 22 (11) 49 (24) \0.05
Recurrent episodes at 48 h 29 (15) 53 (26) \0.05
Data are reported as absolute (n) and relative (%) frequency. P refers
to the statistical signiﬁcance of the difference between the two study
drugs
Fig. 1 Cumulative hazard of recurrence over 48 h during treatment
with frovatriptan or comparators, in the 187 patients of the intention-
to-treat (ITT) population. Data are shown separately for frovatriptan
(continuous line) and for the three comparators pooled together
(dotted line). P value refers to the statistical signiﬁcance of the
between-treatment difference
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123explained, at least in part, by differences in the pharma-
cokinetics of frovatriptan with respect to the other triptans.
Frovatriptan has a longer elimination half-life than riza-
triptan, zolmitriptan and almotriptan, this possibly
explaining why frovatriptan, unlike the other tested trip-
tans, greatly reduced the risk of recurrence [12].
This is the ﬁrst analysis of head-to-head, double-blind,
randomized trials of frovatriptan versus other triptans in
women suffering from menstrual migraine. Our study and a
retrospective analysis of almotriptan versus zolmitriptan are
the only available double-blind, randomized studies com-
paring the efﬁcacy of two triptans [13]. In a previous publi-
cation treatment of 136 women with almotriptan 12.5 mg
and of 119 women with zolmitriptan 2.5 mg resulted in
similar proportions of 2 h pain relief and pain free as well as
2–24 h recurrences between the two groups [13].
Though we acknowledge that the strength of our results
might be weakened by the post hoc nature of the analysis,
no such prospective studies are yet available or have been
planned. Our results encourage the design and implemen-
tation of larger direct comparative randomized clinical
trials evaluating triptan efﬁcacy in female migraineurs.
In terms of safety, in our pooled analysis, treatment with
frovatriptan and other triptans was associated with a similar
low prevalence of adverse drug reactions. This reinforces
evidence from prior placebo controlled or head-to-head
trials, namely that frovatriptan, used for immediate or
repeated sustained use, is one of the best tolerated among
triptans [14–19].
In conclusion, our analysis of individual data of double-
blind, randomized, crossover trials suggests that frova-
triptan and other widely employed triptans share a similar
efﬁcacy in the immediate treatment of acute attack of
menstrual migraine. However, frovatriptan seems to offer
the advantage of a lower risk of recurrence and thus a more
sustained effect than the other triptans.
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